FDA Greenlights Lurbinectedin Combination for Extensive-Stage Small Cell Lung Cancer Maintenance, Extending Survival

The U.S. Food and Drug Administration (FDA) has announced the approval of lurbinectedin (Zepzelca; Jazz Pharmaceuticals) in combination with atezolizumab (Tecentriq; Genentech), or atezolizumab and hyaluronidase-tqjs (Tecentriq Hybreza), for the maintenance treatment of adults with extensive-stage small cell lung cancer (ES-SCLC). This significant approval offers a new lifeline for patients whose disease has not progressed following initial first-line induction therapy.

A New Hope for ES-SCLC Patients

ES-SCLC is a particularly aggressive form of lung cancer, affecting approximately 30,000 Americans annually, and historically carries a poor prognosis. The newly approved regimen aims to provide a more durable response after initial chemotherapy and immunotherapy. The first-line induction therapy typically involves atezolizumab, or atezolizumab and hyaluronidase, combined with carboplatin and etoposide.

IMforte Trial: Robust Evidence for Efficacy and Safety

The FDA’s decision was based on compelling efficacy and safety data from the randomized, multicenter, open-label, Phase 3 IMforte (NCT05091567) clinical trial. This pivotal study enrolled 438 ES-SCLC patients whose disease had not progressed after 4 cycles of induction therapy. Patients were then randomized to receive either the lurbinectedin-atezolizumab combination or atezolizumab alone until disease progression or unacceptable toxicity.

The primary efficacy outcomes, Overall Survival (OS) and Progression-Free Survival (PFS), demonstrated clear superiority for the combination arm:

Overall Survival (OS):
- Combination Arm: Median OS of 13.2 months (95% CI 11.9–15.4)
- Atezolizumab Alone Arm: Median OS of 10.6 months (95% CI 9.5–12.2)
- Hazard Ratio (HR): 0.73 (95% CI 0.57–0.95); P = .0174 – indicating a statistically significant reduction in the risk of death with the combination.
Progression-Free Survival (PFS):
- Combination Arm: Median PFS of 5.4 months (95% CI 4.2–5.8)
- Atezolizumab Alone Arm: Median PFS of 2.1 months (95% CI 1.6–2.7)
- HR: 0.54 (95% CI 0.43–0.67); P < .0001 – demonstrating a highly significant reduction in the risk of disease progression or death.

These results unequivocally establish the benefit of adding lurbinectedin to the maintenance regimen for ES-SCLC.

Key Safety Information for Healthcare Professionals

While generally well-tolerated, the combination regimen did show a higher incidence of treatment-related adverse events (TEAEs):

TEAEs: Approximately 83.5% of patients in the combination arm experienced TEAEs, compared to 40.0% in the atezolizumab-alone arm.
Discontinuation Due to AEs: Treatment discontinuation due to AEs occurred in 6.2% of combination arm patients versus 3.3% in the atezolizumab-alone arm.
No New Safety Signals: Importantly, investigators observed no new or unexpected safety signals.

However, healthcare professionals, particularly pharmacists, must be aware of the specific warnings associated with these drugs:

Lurbinectedin (Zepzelca): The prescribing information includes warnings for myelosuppression (bone marrow suppression), hepatotoxicity (liver damage), extravasation (drug leakage from a blood vessel) resulting in tissue necrosis, and embryo-fetal toxicity.
Atezolizumab (Tecentriq) and Atezolizumab and Hyaluronidase (Tecentriq Hybreza): These immunotherapy agents carry boxed warnings for severe immune-mediated adverse events and potential complications following allogeneic hematopoietic stem cell transplantation.

Recommended Dosage and Administration

The FDA specifies the following dosages:

Lurbinectedin: 3.2 mg/m2 by intravenous (IV) infusion every 21 days until unacceptable toxicity or disease progression.
Atezolizumab: 840 mg every 2 weeks, 1200 mg every 3 weeks, or 1680 mg every 4 weeks by IV infusion.
Atezolizumab and Hyaluronidase: 1875 mg of atezolizumab and 30,000 units of hyaluronidase administered subcutaneously every 3 weeks.

This approval follows a priority review designation granted in June 2025, underscoring the FDA’s recognition of the urgent unmet need for effective treatments in ES-SCLC. This new regimen represents a significant advancement, offering patients a novel and effective management option that could meaningfully improve outcomes.